Jennifer Crombie

Featured in: Favicon

wiley.com

ascopubs.org Favicon

cancernetwork.com Favicon

onclive.com Favicon

survivornet.com Favicon

targetedonc.com Favicon

onlinelibrary.wiley.com

Articles

FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Sep 16, 2024 | onclive.com | Jennifer Crombie

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
Future Directions and Unmet Needs in Relapsed/Refractory MCL

Feb 20, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Future Directions and Unmet Needs in Relapsed/Refractory MCLA panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Sequencing Therapies in the Third-Line and Beyond Setting for MCL

Feb 13, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Sequencing Therapies in the Third-Line and Beyond Setting for MCLA panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Current Treatment Options in Third-line MCL

Feb 13, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Current Treatment Options in Second-line MCL

Feb 6, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

SOC Role of Frontline Nivolumab Plus Cabozantinib in Metastatic RCC Confirmed With Long-Term Efficacy ResultsDr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC
ASH 2023 Updates on Frontline Therapies in MCL

Feb 6, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah
Current Treatment Options in First-Line MCL

Jan 30, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCCSubcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCCDr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCCAdjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC
Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Jan 23, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon CancerctDNA Is Predictive of DFS, Offers Prognostic Tool in CRCFrontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRCDr Li on the Use of ADG126 With Pembrolizumab in MSS CRC
Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

Jan 23, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Sequencing Immunotherapy in the Third-line and Beyond Setting for FLPeter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

Jan 16, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FLA panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.